Full-Time

Technology and Solutions Strategist

Posted on 6/20/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Rochester, NY, USA + 5 more

More locations: Vermont, USA | Concord, NH, USA | Albany, NY, USA | Buffalo, NY, USA | Maine, USA

Hybrid

Hybrid role with 50-75% travel; regional focus in Upstate New York and New England.

Category
Business & Strategy (1)
Required Skills
Sales
Data Analysis
Requirements
  • Associates degree in Veterinary Technology or bachelor’s degree in an Animal Health field preferred.
  • Minimum of five years Animal Health equipment and/or solution sales experience with a track record of success in managing and growing accounts.
  • Deep knowledge of technology and solutions and how to orchestrate them into a positive user experience as well as thorough understanding of market dynamics, evolving trends, and the needs of key stakeholders and customers.
  • Thorough understanding of the organization and relevant team expertise to best serve customer and business needs.
  • Strong rapport and ability to work across the organization.
  • Requires a demonstrated track record of successful account management skills. Must be comfortable working independently and in partnership with others while servicing customers, and regularly applying business judgment to application of company policies.
  • Thorough understanding of technology and solutions and how to orchestrate them into customer workflows and a positive user experience
  • Self-motivated, strong interpersonal, multitasking, organizational and project planning skills
  • Significant experience in complex sales cycle
  • Travel requirements greater than 50%
Responsibilities
  • Achieve consolidated revenue budget and strategic placement goals for platform components, innovative solutions & services, and capital equipment.
  • Lead and support Territory Managers in developing and closing sales opportunity for platform components, innovative services and capital equipment.
  • Work closely with field sales to identify technology solution and equipment opportunities with existing and potential customers using market intelligence and analytics.
  • Use consultative selling techniques to strategize and educate customers on new technologies and solutions that will improve short and long-term success for customers.
  • Track and report on set of performance metrics for product portfolio, such as customer conversations, win rate, number of new technology or solutions placed, potential opportunities, etc.
  • Partner with development teams to convey product/solution information and feedback from the field and customers to drive continuous improvement and opportunities with strategic solutions platforms.
  • Maintain an in-depth knowledge of customer workflows and MWI’s platform components and products, and understand how they weave together to orchestrate a positive user experience
  • Be a sales pipeline tool user and evangelist, and possess the capacity to navigate reporting and maximize capabilities
  • Develop and Execute sales strategies with high level of ability

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Your Connections

People at Cencora who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Biosimilar launches increase demand for access, education, and patient-support services.
  • Specialty medicine growth supports higher-margin revenue across oncology and ophthalmology.
  • AI-enabled operations can improve inventory accuracy, forecasting, and supply-chain efficiency.

What critics are saying

  • Manufacturer price cuts continue compressing revenue growth and distributor economics.
  • Customer losses from mail-order pharmacy and oncology channels weaken volume stability.
  • Integrating EyeSouth and other specialty assets creates execution and retention risk.

What makes Cencora unique

  • Cencora combines drug distribution, specialty pharmacy, and commercialization support.
  • OneOncology and Retina Consultants of America deepen specialty-care integration.
  • Nucleus inventory pilots add workflow software, hardware, and billing automation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.